Docoh
Loading...

82 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
stock units; along with 2,007,853 reserved for future issuance under our existing stock option and equity incentive compensation plans. On August 20 … to equity incentive plans and our ATM Program, as of the date of this proxy statement, we have no current plans, arrangements or understandings
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
; along with 2,107,853 reserved for future issuance under our existing stock option and equity incentive compensation plans. On August 20, 2021, we … incentive plans and our ATM Program, as of the date of this proxy statement, we have no current plans, arrangements or understandings regarding
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
shares of common stock reserved for future awards under our equity incentive plans as of June 30, 2021. To the extent that any of these outstanding … our equity incentive plans at prices below the public offering price per share in this offering, there will be further dilution to new investors
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, we issued 324,360 restricted stock awards under the 2019 Omnibus Incentive Plan to our employees and directors, of which 214,078 shares of common
S-8
EX-5.1
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Registration of securities for employees
4:02pm
to the Company’s Amended and Restated 2019 Omnibus Incentive Plan (the “Plan”), incorporated by reference as Exhibit 4.1 to the Registration Statement
S-8
m2mlj
30 Jun 21
Registration of securities for employees
4:02pm
8-K
o3g4v70g09
10 Jun 21
Submission of Matters to a Vote of Security Holders
5:30pm
DEF 14A
wz2un6a99z3wl
22 Apr 21
Definitive proxy
2:00pm
10-K/A
51ewb9evt8gzu3o
7 Apr 21
Annual report (amended)
4:23pm
10-K
zgsd xxzvgs56z
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
c0f80pg62g sq
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
yhzdk2js6g3wjidn6
12 Nov 20
Quarterly report
4:01pm
8-K
EX-10.1
cix5197lxk66ma8
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-1.1
iw4yp 7kgzg34k
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
8j3t1x1 l1orz
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
k5le13nis7 ddj9
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
1sgf2q2v u7hgtrw
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
g3fawg xcc
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.4
43h2l
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
z8s1pb6s h623uy
16 Sep 20
IPO registration (amended)
8:00pm